Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rom Leidner

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Oral and Maxillofacial Surgery Clinics of North America|November 20, 2018
Immunotherapy for Head and Neck CancerFelix Sim, Rom Leidner, Richard Bryan Bell
Hematology/Oncology Clinics of North America|March 6, 2019
Immunotherapy for Head and Neck CancerFelix Sim, Rom Leidner, Richard Bryan Bell
Journal for Immunotherapy of Cancer|November 24, 2016
Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810Gerald S Falchook, Rom Leidner, Elizabeth Stankevich, et al.
Frontiers in Oncology|July 5, 2021
Explant Modeling of the Immune Environment of Head and Neck CancerShay Sharon, Thomas Duhen, Shelly Bambina, et al.
Clinical & Translational Immunology|May 20, 2016
OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancerRyan Montler, R Bryan Bell, Colin Thalhofer, et al.
European Journal of Cancer (Oxford, England : 1990)|July 10, 2025
Approaches to overcome the current treatment plateau in immunotherapyAnna Maria Di Giacomo, Renzo Canetta, John Connolly, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodiesDavid Knorr, Rom Leidner, Shawn Jensen, et al.
The New England Journal of Medicine|June 1, 2022
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic CancerRom Leidner, Nelson Sanjuan Silva, Huayu Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2021
Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid TumorsDavid S Hong, Olivier Rixe, Vi K Chiu, et al.
Journal for Immunotherapy of Cancer|October 31, 2023
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumorsRom Leidner, Kevin Conlon, Douglas G McNeel, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Oral and Maxillofacial Surgery Clinics of North America|November 20, 2018
Immunotherapy for Head and Neck CancerFelix Sim, Rom Leidner, Richard Bryan Bell
Hematology/Oncology Clinics of North America|March 6, 2019
Immunotherapy for Head and Neck CancerFelix Sim, Rom Leidner, Richard Bryan Bell
Journal for Immunotherapy of Cancer|November 24, 2016
Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810Gerald S Falchook, Rom Leidner, Elizabeth Stankevich, et al.
Frontiers in Oncology|July 5, 2021
Explant Modeling of the Immune Environment of Head and Neck CancerShay Sharon, Thomas Duhen, Shelly Bambina, et al.
Clinical & Translational Immunology|May 20, 2016
OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancerRyan Montler, R Bryan Bell, Colin Thalhofer, et al.
European Journal of Cancer (Oxford, England : 1990)|July 10, 2025
Approaches to overcome the current treatment plateau in immunotherapyAnna Maria Di Giacomo, Renzo Canetta, John Connolly, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodiesDavid Knorr, Rom Leidner, Shawn Jensen, et al.
The New England Journal of Medicine|June 1, 2022
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic CancerRom Leidner, Nelson Sanjuan Silva, Huayu Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2021
Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid TumorsDavid S Hong, Olivier Rixe, Vi K Chiu, et al.
Journal for Immunotherapy of Cancer|October 31, 2023
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumorsRom Leidner, Kevin Conlon, Douglas G McNeel, et al.
Pageof 3